PolyNovo (ASX:PNV): FY26 Revenue, NovoSorb Sales and Manufacturing Plans

Aditi Sarkar

02 November 2026 06:10 PM AEDT

PolyNovo (ASX:PNV): FY26 Revenue, NovoSorb Sales and Manufacturing Plans

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo reported FY26 total Revenue of AUD 150.0 million.
Commercial sales grew 16.7% YoY to AUD 138.4 million.
FY26 Operating Cash Flow was AUD 23.1 million.
Manufacturing and regulatory activities feature in FY27 priorities.

PolyNovo develops and distributes medical devices based on its NovoSorb polymer technology, with applications in burns and complex wound management. PolyNovo Limited (ASX:PNV) shares closed at AUD 0.905 on 2 November 2026. Its August 2026 full-year results detailed commercial sales growth, positive operating cash flow and work on Manufacturing capacity and product registrations. Subsequent 2026 company updates also addressed changes to Leadership and priorities for FY27.

NovoSorb Products and Geographic Markets

PolyNovo Limited (ASX:PNV) sells NovoSorb Biodegradable Temporising Matrix, known as BTM, and NovoSorb MTX for medical applications involving tissue repair. The company operates directly in several markets, including Australia and the United States, and uses distributors in other territories. Its FY26 reporting distinguishes United States sales from sales across the rest of the world. Different treatment settings, clinical evidence requirements and regulatory permissions affect the markets accessible to each product. Revenue depends on hospital procurement, clinician adoption and product availability.

FY26 Financial Results

For the year ended 30 June 2026, PolyNovo reported total revenue of AUD 150.0 million, up 16.1% YoY, and commercial sales of AUD 138.4 million, up 16.7% YoY. United States commercial sales were AUD 102.1 million, while rest-of-world commercial sales were AUD 36.3 million. EBITDA was AUD 12.1 million, compared with AUD 11.2 million in FY25. Net profit after tax was AUD 7.3 million, down from AUD 13.2 million; the report noted a difference in income tax treatment between the periods. PolyNovo Limited (ASX:PNV) reported operating cash inflow of AUD 23.1 million and free cash flow of AUD 9.4 million.

Manufacturing, Registrations and Strategy

The FY26 Annual Report states that construction of PolyNovo’s expanded Port Melbourne manufacturing Facility was completed, with the transition dependent on validation and other requirements. Its results materials also described work towards a United States premarket approval submission for use of NovoSorb BTM in full-thickness burns. The company’s October 2026 Annual General Meeting materials discussed a proposed United States outpatient product launch and a phased transition to the new facility during FY27. These milestones remain subject to execution, regulatory and operating conditions.

Costs, Regulation and Business Risks

PolyNovo’s FY26 gross Margin was 89.0%, compared with 95.6% in FY25. The decline illustrates why sales growth cannot be treated as identical to margin expansion. Production efficiency, commercial staffing, research costs and foreign currency movements can affect earnings. The company must also meet medical-device quality and regulatory requirements across markets. Completion of building works does not automatically mean a manufacturing site can immediately Supply all commercial demand.

What to Watch During FY27

The company’s stated priorities include regulatory work for BTM, outpatient commercial arrangements, MTX adoption and the staged manufacturing transition. Additional reporting can show progress against each milestone and whether cash generation continues after capital expenditure. PolyNovo Limited (ASX:PNV) has not provided formal FY27 financial guidance in its October annual general meeting presentation. Accordingly, no revenue or profit forecast is inferred here. Upcoming results may provide updated information on gross margin, expense management and regional commercial sales.

Key Insights

FY26 reporting showed higher PolyNovo revenue and commercial sales alongside positive operating and free cash flow. Net profit decreased, and gross margin narrowed on the reported basis. Manufacturing validation, market access and regulatory steps remain separate tasks, each with potential effects on spending and timing. Future disclosures will indicate whether the 2026 operational initiatives translate into sustained financial outcomes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.